The association of aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein (MOG) antibodies (Ab) with specific acquired demyelination syndromes (ADS) is now well established. The identification of AQP4-Ab in neuromyelitis optica spectrum disorder (NMOSD) 1 has improved the diagnosis and led to more rapid initiation of treatment. The most recent criteria for the diagnosis of NMOSD stratifies patients according to the presence or absence of AQP4-Ab.
The association of aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein (MOG) antibodies (Ab) with specific acquired demyelination syndromes (ADS) is now well established. The identification of AQP4-Ab in neuromyelitis optica spectrum disorder (NMOSD) 1 has improved the diagnosis and led to more rapid initiation of treatment. The most recent criteria for the diagnosis of NMOSD stratifies patients according to the presence or absence of AQP4-Ab. 2 Two studies looking at the prevalence of AQP4-Ab in paediatric patients presenting with a first episode of demyelination have identified these in only 0.7% (2/279) 3 to 4.5% (3/64) 4 of children, which may reflect the rarity of NMOSD in certain populations. A recent nationwide study of Japanese children identified AQP4-Ab in 1 out of 12 patients with multiple sclerosis and three out of six patients with NMOSD who were tested. 5 Nevertheless, the severity of NMOSD and the role for specific therapies prompts testing for AQP4-Ab in all children with ADS.
More recently, MOG-Ab have been reported in about 40% 6 of children at first presentation of an acquired demyelinating syndrome, with two studies from the UK/ France 7 and the Netherlands 8 suggesting that MOG-Ab identified at onset are associated with a non-multiple sclerosis disease course. Although initially reported in predominantly monophasic disease, MOG-Ab have been detected in patients with multiphasic disseminated encephalomyelitis, 9 recurrent optic neuritis, 10 and acute disseminated encephalomyelitis (ADEM) followed by recurrent or monophasic optic neuritis, 11 and in both adults and children 12 with NMOSD without AQP4-Ab. Two recent reports identified MOG-Ab and AQP4-Ab in 28 out of 35 13 and 34 out of 48 14 children with non-multiple sclerosis relapsing demyelination.
Both MOG and AQP4 antibodies have been routinely requested in all children with ADS in our centres. In view of the overlap at presentation with other non-ADS neurological syndromes, these antibodies were also requested for patents with a range of non-ADS neurological syndromes. Our primary objective was to establish the clinical relevance of these antibodies with the secondary aim to explore the clinical phenotypes associated with AQP4 and MOG antibodies in an unselected cohort of children with ADS.
METHOD
Between 2012 and 2017, 371 serum samples were sent from Evelina Children's Hospital (n=92), Great Ormond Street Children's Hospital (n=192), and Birmingham Children's Hospital (n=87) for MOG-Ab and AQP4-Ab testing. Patients were identified from the respective pathology department databases. All patients were tested clinically, but not always at the time of first presentation. Patients had undergone brain and spinal cord magnetic resonance imaging (MRI) according to local MRI protocols. The clinical data comprising demographic information, clinical features at presentation, discharge and follow-up, and results of laboratory testing and neuroimaging were compiled (SD, TR) and presented to two paediatric neurologists (SW, YH), who were blinded to the antibody results. They classified the patients according to established criteria 15 to either ADS or non-ADS aetiology. Within the ADS group, patients were further classified (based on the neurological examination and without reference to neuroimaging features) as optic neuritis, transverse myelitis, polyfocal neurological deficits associated with encephalopathy (ADEM), or polyfocal deficits without encephalopathy.
Relapsing cases were assigned the following diagnostic categories: (1) Serum AQP4-Ab and MOG-Ab were tested as part of the routine clinical assessment of children with demyelinating diseases. Serum was sent to the Clinical Neuroimmunology service at the Oxford Radcliffe Hospital Trust, where AQP4-Ab and MOG-Ab were tested using live cellbased assays, as previously described. 7, 16 No cerebrospinal fluid samples were available from these children for further analysis.
In order to evaluate if patients with monophasic disease are more likely to have transiently elevated levels of autoantibodies, as previously reported, 17 we additionally report children who had a sample taken acutely and a repeat sample at 3-to 6-months follow-up. Results were assigned into positive and negative diagnostic categories as reported by the reference laboratory.
Statistical analysis
Statistical analysis was performed using the commercially available software GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA, USA). Nonparametric statistical tests (Mann-Whitney U tests) were used for continuous distri- 
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RESULTS
The clinical records for each patient were examined and the diagnoses established. The results are shown in Figure 1 and summarized in Table I . Of the 371 children for whom antibody testing was requested, 237 (63.9%) children were diagnosed with ADS: 117 (49.4%) were monophasic and 120 (50.6%) were relapsing. Overall, 90 (38%) of the 237 patients in the ADS group had antibodies to either MOG or AQP4 compared to two in the non-ADS group (p<0.001, Fishers exact). MOG-Ab were identified in 76 patients (32.2%), all with ADS. AQP4-Ab were identified in 16 cases, 14 patients with NMOSD, and two with systemic lupus erythematosus (SLE) and no evidence of CNS demyelination (both currently on maintenance immunosuppression for SLE). MOG-Ab had 100 specificity (95% confidence interval [CI]: 97.28-100.00) and 100% positive predictive value for ADS, with 32.2% sensitivity (95% CI: 26.29-38.57).
What this paper adds
• Myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) are highly specific for acquired demyelinating syndromes (ADS).
• Myelin oligodendrocyte glycoprotein antibodies are not identified in children with peripheral demyelination or genetic leukodystrophies/hypomyelination.
• Up to 48% of MOG-Ab ADS paediatric patients relapse, higher than previously thought.
• Seroconversion to MOG-Ab negative status is infrequent; patients may test MOG-Ab positive at follow-up sampling even when asymptomatic.
• Myelin oligodendrocyte glycoprotein antibodies status should only be used in conjunction with the clinical information to guide maintenance therapy.
AQP4-Ab had 99.4% specificity (95% CI: 97.87-99.93) for NMOSD and 42.42% sensitivity (95% CI 25.48-60.78). Of the 33 children with NMOSD, 14 were AQP4-Ab positive, 13 were MOG-Ab positive, and 6 were seronegative. All 54 patients with relapsing remitting multiple sclerosis were negative to both autoantibodies. Of note, of the relapsing non-multiple sclerosis phenotypes, 76.5% (52/68) were antibody positive. Of the non-multiple sclerosis ADS, clinical relapses were reported in all patients with AQP4-Ab, 38 out of 76 (50%) children with MOG-Ab and 14 out of 80 (17.5%) of seronegative ADS (Fig. 1) .
MOG and AQP4 antibodies across the different ADS
A summary of the results is illustrated in Figure 1 .
Myelin oligodendrocyte glycoprotein antibodies were detected in 45 out of 70 (64.3%) patients presenting with ADEM. Relapse after ADEM was observed in 25 out of 70 (35.7%). The final diagnoses were multiphasic disseminated encephalomyelitis (n=16), NMOSD (n=6), and ADEM-optic neuritis (n=3). Of the relapsing ADEM patients, 24 out of 25 had MOG-Ab.
Of the 65 patients presenting with optic neuritis, 28 (43.1%) had MOG-Ab and 2 (3.1%) had AQP4-Ab. Twelve patients were diagnosed with multiple sclerosis. Of the 24 non-multiple sclerosis relapsing patients (diagnosed with NMOSD and relapsing optic neuritis), 12 had MOGAb and 2 AQP4-Ab.
There were 50 patients who presented with transverse myelitis. Of these, 36 out of 50 (72%) had a monophasic disease. MOG-Ab was only identified in 3 out of 50 (6%, all monophasic). Of the 14 patients who relapsed, three were diagnosed with relapsing remitting multiple sclerosis and eight had AQP4-Ab. These eight patients were subsequently diagnosed with NMOSD. Fifty-two patients presented with clinically isolated syndrome. Relapsing remitting multiple sclerosis was the most frequent diagnosis in 38 out of 52 (74.5%) of these patients. Four went on to be diagnosed with NMOSD, all of whom presented initially with brainstem syndrome and were AQP4-Ab positive.
Serial measurements of antibodies
Of the 14 patients with AQP4-Ab NMOSD, serial samples were available for 13 patients with a median of five samples per patient (interquartile range [IQR] 2.5-11). Median follow-up time from first antibody testing was 50.5 months (range 7-106mo). Eight patients remained seropositive throughout follow-up. The remaining five patients' seropositivity fluctuated to negative but returned to positive with relapses.
A total of 43 MOG-Ab positive patients had longitudinal testing over the disease course. Of these, 16 patients were monophasic and 27 relapsing. There was a trend to a longer follow-up time in patients with relapsing disease compared to monophasic disease (median 48mo, IQR 31-64mo vs median of 36mo, IQR 21-54mo, p=0.170).
Of the 16 children with MOG-Ab monophasic ADS (median 2 samples, range 2-4), 13 remained seropositive throughout the follow-up period. Patients with monophasic illness stayed MOG-Ab positive throughout the followup, for a median of 9 months (range 6-51mo) despite not relapsing. Of the 27 children with MOG-Ab relapsing ADS (median 3 samples, range 2-15), 22 remained MOGAb positive. Two children with relapsing ADEM became seronegative in between attacks. None of the children were MOG-Ab negative at time of relapse of ADS. Persistent levels at 6 months were seen in both monophasic and relapsing patients (11/14 vs 10/13, p=1.0).
DISCUSSION
In this large cohort of 371 children who underwent AQP4-Ab and MOG-Ab testing, we demonstrated that both antibodies are clinically relevant in ADS. The testing of 135 non-ADS cases, which included patients with a range of neurological disorders including peripheral neuropathies and neurodegenerative disorders such as leukodystrophies, has allowed us to demonstrate that the current MOG-Ab assay, used clinically, is both sensitive and specific to ADS. Our results were strikingly similar to an Austrian/German cohort identifying MOG-Ab in 65 out of 210 (31%) of children with ADS. 13 Similar to the results identified here, relapses occurred in children who become seronegative (reconversion to positive), and there were children who remained relapse free despite very persistently raised antibody titres. A direct comparison with a previous report of transient MOG-Ab positivity in patients with monophasic ADEM is difficult as a different cut-off for positivity than the assay used here was used. 17 Although AQP4-Ab are strongly associated with a relapsing disease in children and adults with NMOSD, 18 at an individual level we did not observe that the antibody positivity could be used to reliably predict the subsequent course of disease. In keeping with other antibody-mediated conditions, such as myasthenia gravis and anti-N-methyl-D-aspartate receptor encephalitis, the data reported here suggest that antibody titres cannot be used in isolation to guide maintenance therapy. Identification of patients who were tested MOGAb negative in between clinical events highlight the need for repeat testing when the child is symptomatic if the clinical phenotype is suggestive of MOG-Ab associated disease.
The two patients with AQP4-Ab who did not fulfil diagnostic criteria for NMOSD 2 had an underlying diagnosis of SLE with CNS involvement, without evidence of demyelination. Although it is possible that the positive results may simply reflect false positivity, the association between AQP4-Ab NMOSD and SLE is well described and is thought to represent shared genetic susceptibility to autoimmune disease. 19, 20 AQP4-Ab have previously been reported in a small percentage of patients with non-CNS SLE without concurrent clinical or radiological signs of demyelination and the antibodies have been shown to persist for many years without causing demyelinating disease. 21 It will be important to observe if the two patients in our cohort develop demyelination in the future as previously reported with patients with myasthenia gravis who despite being positive for AQP4-Ab did not present with NMOSD for over 10 years. 22 None of the patients were double positive for both MOG and AQP4 antibodies and all children with multiple sclerosis were negative for both autoantibodies.
Limitations of our study include its retrospective design. A prospective study would have allowed us to standardize the data collection and timing of samples across the different sites. We did not control for treatment effect on antibody levels. Furthermore, a proportion of the patients were only diagnosed at the time of relapse so the antibody results were not available at disease onset. As the aim of this study was to look at the clinical utility of the test, we have categorized the antibody results into positive and negative (as reported clinically) and have not evaluated if fluctuation in antibody titres during the disease course is important. The relationship between MOG-Ab titres and clinical disease activity, however, remains an area of active investigation, with a recent report suggesting that a high MOG-Ab titre (≥1:1280) predicted a recurrent non-multiple sclerosis course with a sensitivity of 46% and a specificity of 86%. 15 The utility and applicability of this is yet to be evaluated clinically in light of challenges of measuring antibody titres beyond a research setting. Additionally, we did not evaluate the clinical utility of cerebrospinal fluid antibody results; one publication has suggested that cerebrospinal fluid antibody titres may correlate better than serum in AQP4-Ab NMOSD. 23 In conclusion, AQP4-Ab were found in children with NMOSD but also in children with SLE who do not have any clinical or radiological features of NMOSD. MOG-Ab were identified in a third of children with ADS but not in children with non-ADS or multiple sclerosis. Half the children with MOG-Ab relapsed, a higher rate of relapsing disease than previously reported by us 7 and others. 24 This is likely because of a longer follow-up time and increased awareness of this phenotype amongst patients previously labelled as having multiple sclerosis. The identification of MOG-Ab in a range of ADS that relapse raises important questions about management. We recently reported a multinational experience of children with relapsing ADS associated with MOG-Ab associated disease accounting for 23.6% of all relapsing ADS. However, the inability currently to predict the probability of relapse and the prolonged intervals between first presentation and relapse, and interattack intervals -in some cases up to 10 years -mandates the careful management of each case individually.
